Tags

Type your tag names separated by a space and hit enter

Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat.
Neurosci Res. 2006 Mar; 54(3):165-70.NR

Abstract

PYY3-36 is a major component of the gut-brain axis and peripheral administration has been reported to exert significant effects on feeding, brain function and is more selective for neuropeptide Y2 receptor. Therefore, we investigated the effects of nocturnal intraperitoneal administration of single doses of PYY3-36 (30 and 100 microg/kg i.p.) on food intake, water intake and the sleep-wake cycle in rats. Sleep recordings were carried out in male Sprague-Dawley rats implanted with cortical electroencephalogram (EEG) and neck electromyogram (EMG) electrodes. The EEG, EMG, food intake and water intake were assessed. The electrographic recordings obtained were scored visually as rapid eye movement (REM) sleep, non-REM (NREM) sleep and wakefulness. PYY3-36 administration 15 min prior to dark onset significantly (p<0.05) increased non-rapid eye movement (NREM) sleep and decreased wakefulness. Analysis of the dark-period at 4-h time intervals showed that nocturnal administration of PYY3-36 (30 and 100 microg/kg) significantly suppressed wakefulness and increased non-REM sleep during the first 4-h time interval. Time spent in wakefulness was significantly decreased after administration of PYY3-36 (30 and 100 microg/kg) when compared with administration of vehicle. In addition, PYY3-36 (30 and 100 microg/kg i.p.) induced an increase in the time spent in NREM sleep. The nocturnal intraperitoneal administration of the lower dose of PYY3-36 (30 microg/kg) also significantly decreased food intake [F (2,23)=4.90, p<0.05] but had no effect on water intake. These findings suggest that PYY3-36 may play an important role in the enhancement of NREM sleep and feeding behavior.

Authors+Show Affiliations

Department of Biosystem Regulation, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Tokyo 101-0062, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16378653

Citation

Akanmu, Moses A., et al. "Neuropeptide-Y Y2-receptor Agonist, PYY3-36 Promotes Non-rapid Eye Movement Sleep in Rat." Neuroscience Research, vol. 54, no. 3, 2006, pp. 165-70.
Akanmu MA, Ukponmwan OE, Katayama Y, et al. Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat. Neurosci Res. 2006;54(3):165-70.
Akanmu, M. A., Ukponmwan, O. E., Katayama, Y., & Honda, K. (2006). Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat. Neuroscience Research, 54(3), 165-70.
Akanmu MA, et al. Neuropeptide-Y Y2-receptor Agonist, PYY3-36 Promotes Non-rapid Eye Movement Sleep in Rat. Neurosci Res. 2006;54(3):165-70. PubMed PMID: 16378653.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat. AU - Akanmu,Moses A, AU - Ukponmwan,Otas E, AU - Katayama,Yoshifumi, AU - Honda,Kazuki, Y1 - 2005/12/27/ PY - 2005/08/24/received PY - 2005/10/18/revised PY - 2005/11/18/accepted PY - 2005/12/28/pubmed PY - 2006/4/29/medline PY - 2005/12/28/entrez SP - 165 EP - 70 JF - Neuroscience research JO - Neurosci Res VL - 54 IS - 3 N2 - PYY3-36 is a major component of the gut-brain axis and peripheral administration has been reported to exert significant effects on feeding, brain function and is more selective for neuropeptide Y2 receptor. Therefore, we investigated the effects of nocturnal intraperitoneal administration of single doses of PYY3-36 (30 and 100 microg/kg i.p.) on food intake, water intake and the sleep-wake cycle in rats. Sleep recordings were carried out in male Sprague-Dawley rats implanted with cortical electroencephalogram (EEG) and neck electromyogram (EMG) electrodes. The EEG, EMG, food intake and water intake were assessed. The electrographic recordings obtained were scored visually as rapid eye movement (REM) sleep, non-REM (NREM) sleep and wakefulness. PYY3-36 administration 15 min prior to dark onset significantly (p<0.05) increased non-rapid eye movement (NREM) sleep and decreased wakefulness. Analysis of the dark-period at 4-h time intervals showed that nocturnal administration of PYY3-36 (30 and 100 microg/kg) significantly suppressed wakefulness and increased non-REM sleep during the first 4-h time interval. Time spent in wakefulness was significantly decreased after administration of PYY3-36 (30 and 100 microg/kg) when compared with administration of vehicle. In addition, PYY3-36 (30 and 100 microg/kg i.p.) induced an increase in the time spent in NREM sleep. The nocturnal intraperitoneal administration of the lower dose of PYY3-36 (30 microg/kg) also significantly decreased food intake [F (2,23)=4.90, p<0.05] but had no effect on water intake. These findings suggest that PYY3-36 may play an important role in the enhancement of NREM sleep and feeding behavior. SN - 0168-0102 UR - https://www.unboundmedicine.com/medline/citation/16378653/Neuropeptide_Y_Y2_receptor_agonist_PYY3_36_promotes_non_rapid_eye_movement_sleep_in_rat_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-0102(05)00300-7 DB - PRIME DP - Unbound Medicine ER -